Extramedullary Relapsed Multiple Myeloma Treatment with 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results

Mehmet Onur Demirkol, Ahu Ozkan, Burcu Ucar, Hans Jurgen Wester, Burhan Ferhanoglu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We created our first national clinical protocol of 177Lu-CXCR4 therapy for patient who have failed to respond to current therapy options. We also calculated the kidney, liver, and tumor dosimetry. The kidney's mean absorbed dose was calculated to be 0.45 Gy/GBq, the calculated radiation absorbed dose of the liver was 0.63 Gy/GBq, and the radiation absorbed doses of the tumors vary between 9.2 and 82 Gy/GBq. 177Lu-CXCR4 therapy produced a promising clinical response in our patient in acceptable radiation dose limits as a treatment option in heavily pretreated patients with advanced multiple myeloma.

Original languageEnglish
Pages (from-to)656-658
Number of pages3
JournalClinical nuclear medicine
Volume46
Issue number8
DOIs
StatePublished - 2021

Keywords

  • CXCR4
  • dosimetry
  • endoradiotherapy
  • multiple myeloma
  • pentixather

Fingerprint

Dive into the research topics of 'Extramedullary Relapsed Multiple Myeloma Treatment with 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results'. Together they form a unique fingerprint.

Cite this